Ketamine and suicidal ideation in depression: Jumping the gun?

Pharmacological Research

Volumn 99, Issue , 2015, Pages 23-35

  Rajkumar, R ^a,b,c   Fam, J ^a   Yeo, E Y M ^a,b,c   Dawe, G S ^a,b,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Singapore Institute for Neurotechnology (SINAPSE) 5F   (Singapore)

Author keywords

Depression; Ketamine; NMDA receptor antagonist; Rapid onset antidepressant; Subanaesthetic dose; Suicidal ideation

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTAMIC ACID; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3; KETAMINE; LITHIUM; MICRORNA 34A; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; PSYCHEDELIC AGENT;

ADD ON THERAPY; ANTIDEPRESSANT ACTIVITY; ARTICLE; AUTOMUTILATION; BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CONDUCT DISORDER; DEPRESSION; DRUG DOSE INCREASE; EVENING DOSAGE; HAMILTON DEPRESSION RATING SCALE; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; PYRAMIDAL NERVE CELL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; TREATMENT RESISTANT DEPRESSION; ANIMAL; BIOLOGICAL MODEL; BRAIN; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PATHOPHYSIOLOGY; PSYCHOLOGICAL MODEL; PSYCHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; DEPRESSION; HALLUCINOGENS; HUMANS; KETAMINE; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; SUICIDAL IDEATION;

EID: 84930640287     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.003     Document Type: Review

References (196)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 5th ed. 2013 American Psychiatric Press Arlington, VA
2. C.A. Claassen, M.H. Trivedi, A.J. Rush, M.M. Husain, S. Zisook, E. Young, A. Leuchter, S.R. Wisniewski, G.K. Balasubramani, and J. Alpert Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the star∗d trial J. Affect. Disord. 97 2007 77 84
3. Z. Rihmer, P. Dome, and X. Gonda The role of general practitioners in prevention of depression-related suicides Neuropsychopharmacol. Hung.: A Magyar Pszichofarmakologiai Egyesulet lapja = Off. J Hung. Assoc. Psychopharmacol. 14 2012 245 251
4. M. Pompili, X. Gonda, G. Serafini, M. Innamorati, L. Sher, M. Amore, Z. Rihmer, and P. Girardi Epidemiology of suicide in bipolar disorders: a systematic review of the literature Bipolar Disord. 15 2013 457 490
5. K. Szanto, B.H. Mulsant, P. Houck, M.A. Dew, and C.F. Reynolds 3rd. Occurrence and course of suicidality during short-term treatment of late-life depression Arch. Gen. Psychiatry 60 2003 610 617
6. H. Jick, J.A. Kaye, and S.S. Jick Antidepressants and the risk of suicidal behaviors JAMA: J. Am. Med. Assoc. 292 2004 338 343
7. C.H. Kellner, M. Fink, R. Knapp, G. Petrides, M. Husain, T. Rummans, M. Mueller, H. Bernstein, K. Rasmussen, K. O'Connor, G. Smith, A.J. Rush, M. Biggs, S. McClintock, S. Bailine, and C. Malur Relief of expressed suicidal intent by ECT: a consortium for research in ECT study Am. J. Psychiatry 162 2005 977 982
8. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
9. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864
10. G.L. Larkin, A.L. Beautrais, and M. Lippmann Rapid treatment of suicide states in the emergency department Injury Prev. 16 2010 A260
11. G.L. Larkin, and A.L. Beautrais A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 14 2011 1127 1131
12. R.B. Price, and S.J. Mathew Does ketamine have anti-suicidal properties? Current status and future directions CNS Drugs 29 2015 181 188
13. L. Reinstatler, and N.A. Youssef Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature Drugs in R&D 15 2015 37 43
14. J.F. Deakin, J. Lees, S. McKie, J.E. Hallak, S.R. Williams, and S.M. Dursun Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch. Gen. Psychiatry 65 2008 154 164
15. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
16. H. Kamiyama, M. Matsumoto, S. Otani, S.I. Kimura, K.I. Shimamura, S. Ishikawa, Y. Yanagawa, and H. Togashi Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway Neuroscience 177 2011 159 169
17. I. Vernaleken, M. Klomp, O. Moeller, M. Raptis, A. Nagels, F. Rosch, W.M. Schaefer, P. Cumming, and G. Grunder Vulnerability to psychotogenic effects of ketamine is associated with elevated d2/3-receptor availability Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 16 2013 745 754
18. N. Gass, A.J. Schwarz, A. Sartorius, E. Schenker, C. Risterucci, M. Spedding, L. Zheng, A. Meyer-Lindenberg, and W. Weber-Fahr Sub-anesthetic ketamine modulates intrinsic bold connectivity within the hippocampal-prefrontal circuit in the rat Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 39 2014 895 906
19. P. Sos, M. Klirova, T. Novak, B. Kohutova, J. Horacek, and T. Palenicek Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression Neuroendocrinol. Lett. 34 2013 287 293
20. S.M. Stahl Mechanism of action of ketamine CNS Spectr. 18 2013 171 174
21. C.A. Browne, and I. Lucki Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Front. Pharmacol. 4 2013 161
22. G. Sanacora, M.A. Smith, S. Pathak, H.L. Su, P.H. Boeijinga, D.J. McCarthy, M.C. Quirk, and Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects Mol. Psychiatry 2013
23. R. Machado-Vieira, G. Salvadore, N. Diazgranados, and C.A. Zarate Jr. Ketamine and the next generation of antidepressants with a rapid onset of action Pharmacol. Therap. 123 2009 143 150
24. J.W. Murrough, and D.S. Charney Cracking the moody brain: lifting the mood with ketamine Nat. Med. 16 2010 1384 1385
25. J.F. Cryan, O.F. O'Leary, and Neuroscience A glutamate pathway to faster-acting antidepressants? Science 329 2010 913 914
26. R.S. Duman, and N. Li A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists Philos. Trans. R. Soc. London Ser. B, Biol. Sci. 367 2012 2475 2484
27. M.J. Niciu, D.F. Ionescu, E.M. Richards, and C.A. Zarate Jr. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder J. Neural Transm. 121 2014 907 924
28. K. Martinowich, D.V. Jimenez, C.A. Zarate Jr., and H.K. Manji Rapid antidepressant effects: moving right along Mol. Psychiatry 18 2013 856 863
29. C. Zarate, R.S. Duman, G. Liu, S. Sartori, J. Quiroz, and H. Murck New paradigms for treatment-resistant depression Ann. N. Y. Acad. Sci. 1292 2013 21 31
30. E.T. Kavalali, and L.M. Monteggia How does ketamine elicit a rapid antidepressant response? Curr. Opin. Pharmacol. 20 2015 35 39
31. L.M. Monteggia, and C. Zarate Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice Curr. Opin. Neurobiol. 30 2015 139 143
32. J. Wang, L. Jing, J.C. Toledo-Salas, and L. Xu Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression Neurosci. Bull. 31 2015 75 86
33. E. Beurel, L. Song, and R.S. Jope Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice Mol. Psychiatry 16 2011 1068 1070
34. N. Wang, G.F. Zhang, X.Y. Liu, H.L. Sun, X.M. Wang, L.L. Qiu, C. Yang, and J.J. Yang Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine J. Mol. Neurosci.: MN 54 2014 211 218
35. H.G. Bernstein, G. Keilhoff, J. Steiner, G. Laube, and B. Bogerts Downregulation of neuregulin 1-ErbB4 signaling and antidepressant properties of ketamine: ErbB4 expressing pyramidal neurons may play a role J. Mol. Neurosci.: MN 55 2015 372 373
36. C. Yang, T. Hong, J. Shen, J. Ding, X.W. Dai, Z.Q. Zhou, and J.J. Yang Ketamine exerts antidepressant effects and reduces IL-1beta and IL-6 levels in rat prefrontal cortex and hippocampus Exp. Therap. Med. 5 2013 1093 1096
37. C.A. Hoeffer, and E. Klann mTOR signaling: at the crossroads of plasticity, memory and disease Trends Neurosci. 33 2010 67 75
38. M. Livingstone, E. Atas, A. Meller, and N. Sonenberg Mechanisms governing the control of MRNA translation Phys. Biol. 7 2014 021001
39. O.H. Miller, L. Yang, C.C. Wang, E.A. Hargroder, Y. Zhang, E. Delpire, and B.J. Hall Glun2b-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine eLife 3 2014 e03581
40. W. Zhou, L. Dong, N. Wang, J.Y. Shi, J.J. Yang, Z.Y. Zuo, and Z.Q. Zhou Akt mediates GSK-3beta phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions Neuroimmunomodulation 21 2014 183 188
41. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, P.F. Cheng, E.T. Kavalali, and L.M. Monteggia NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
42. L.M. Monteggia, E. Gideons, and E.T. Kavalali The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine Biol. Psychiatry 73 2013 1199 1203
43. S.X. Xu, Z.Q. Zhou, X.M. Li, M.H. Ji, G.F. Zhang, and J.J. Yang The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine Behav. Brain Res. 253 2013 305 309
44. X. Yang, Q. Yang, X. Wang, C. Luo, Y. Wan, J. Li, K. Liu, M. Zhou, and C. Zhang MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine Neuromolecular Med. 16 2014 594 605
45. M. Alonso, J.H. Medina, and L. Pozzo-Miller Erk1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal ca1 pyramidal neurons Learn. Memory 11 2004 172 178
46. M.D. Amaral, and L. Pozzo-Miller TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation J. Neurosci.: Off. J. Soc. Neurosci. 27 2007 5179 5189
47. C.S. Rex, C.Y. Lin, E.A. Kramar, L.Y. Chen, C.M. Gall, and G. Lynch Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus J. Neurosci.: Off. J. Soc. Neurosci. 27 2007 3017 3029
48. J. Jaworski, L.C. Kapitein, S.M. Gouveia, B.R. Dortland, P.S. Wulf, I. Grigoriev, P. Camera, S.A. Spangler, P. Di Stefano, J. Demmers, H. Krugers, P. Defilippi, A. Akhmanova, and C.C. Hoogenraad Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity Neuron 61 2009 85 100
49. V. Kumar, M.X. Zhang, M.W. Swank, J. Kunz, and G.Y. Wu Regulation of dendritic morphogenesis by ras-pi3k-Akt-mTOR and ras-mapk signaling pathways J. Neurosci.: Off. J. Soc. Neurosci. 25 2005 11288 11299
50. W. Zhou, N. Wang, C. Yang, X.M. Li, Z.Q. Zhou, and J.J. Yang Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex Eur. Psychiatry: J. Assoc. Eur. Psychiatrists 29 2014 419 423
51. L. Akinfiresoye, and Y. Tizabi Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR Psychopharmacology (Berlin) 230 2013 291 298
52. V. Tedesco, C. Ravagnani, D. Bertoglio, and C. Chiamulera Acute ketamine-induced neuroplasticity: ribosomal protein s6 phosphorylation expression in drug addiction-related rat brain areas Neuroreport 24 2013 388 393
53. Z. Zhou, G. Zhang, X. Li, X. Liu, N. Wang, L. Qiu, W. Liu, Z. Zuo, and J. Yang Loss of phenotype of parvalbumin interneurons in rat prefrontal cortex is involved in antidepressant- and propsychotic-like behaviors following acute and repeated ketamine administration Mol. Neurobiol. 51 2015 808 819
54. J.C. Zhang, S.X. Li, and K. Hashimoto R (-)-ketamine shows greater potency and longer lasting antidepressant effects than s (+)-ketamine Pharmacol. Biochem. Behav. 116 2014 137 141
55. R. Paul, N. Schaaff, F. Padberg, H.J. Moller, and T. Frodl Comparison of racemic ketamine and s-ketamine in treatment-resistant major depression: report of two cases World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry 10 2009 241 244
56. N.G. Burdett, D.K. Menon, T.A. Carpenter, J.G. Jones, and L.D. Hall Visualisation of changes in regional cerebral blood flow (RCBF) produced by ketamine using long the gradient-echo sequences: preliminary results Magn. Reson. Imaging 13 1995 549 553
57. C.L. Littlewood, N. Jones, M.J. O'Neill, S.N. Mitchell, M. Tricklebank, and S.C. Williams Mapping the central effects of ketamine in the rat using pharmacological MRI Psychopharmacology (Berlin) 186 2006 64 81
58. C.L. Chin, J. Upadhyay, G.J. Marek, S.J. Baker, M. Zhang, M. Mezler, G.B. Fox, and M. Day Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals J. Pharmacol. Exp. Therap. 336 2011 709 715
59. S.A. Perrine, F. Ghoddoussi, M.S. Michaels, I.S. Sheikh, G. McKelvey, and M.P. Galloway Ketamine reverses stress-induced depression-like behavior and increased gaba levels in the anterior cingulate: An 11.7t h-mrs study in rats Progress Neuro-psychopharmacol. Biol. Psychiatry 51C 2013 9 15
60. R. Machado-Vieira, P. Yuan, N. Brutsche, N. DiazGranados, D. Luckenbaugh, H.K. Manji, and C.A. Zarate Jr. Brain-derived neurotrophic factor and initial antidepressant response to an n-methyl-d-aspartate antagonist J. Clin. Psychiatry 70 2009 1662 1666
61. V. Ricci, G. Martinotti, F. Gelfo, F. Tonioni, C. Caltagirone, P. Bria, and F. Angelucci Chronic ketamine use increases serum levels of brain-derived neurotrophic factor Psychopharmacology (Berlin) 215 2011 143 148
62. W.C. Duncan, S. Sarasso, F. Ferrarelli, J. Selter, B.A. Riedner, N.S. Hejazi, P. Yuan, N. Brutsche, H.K. Manji, G. Tononi, and C.A. Zarate Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 16 2013 301 311
63. C.N. Haile, J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, A. Foulkes, S. Iqbal, J.J. Mahoney, R. De La Garza, D.S. Charney, T.F. Newton, and S.J. Mathew Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 17 2014 331 336
64. J.K. Rybakowski, A. Permoda-Osip, M. Skibinska, R. Adamski, and A. Bartkowska-Sniatkowska Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum. Psychopharmacol. 28 2013 87 90
65. O.M. Doyle, S. De Simoni, A.J. Schwarz, C. Brittain, O.G. O'Daly, S.C. Williams, and M.A. Mehta Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents J. Pharmacol. Exp. Therap. 345 2013 151 160
66. S. De Simoni, A.J. Schwarz, O.G. O'Daly, A.F. Marquand, C. Brittain, C. Gonzales, S. Stephenson, S.C. Williams, and M.A. Mehta Test-retest reliability of the bold pharmacological MRI response to ketamine in healthy volunteers Neuroimage 64 2013 75 90
67. P.J. Carlson, N. Diazgranados, A.C. Nugent, L. Ibrahim, D.A. Luckenbaugh, N. Brutsche, P. Herscovitch, H.K. Manji, C.A. Zarate Jr., and W.C. Drevets Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study Biol. Psychiatry 73 2013 1213 1221
68. A.C. Nugent, N. Diazgranados, P.J. Carlson, L. Ibrahim, D.A. Luckenbaugh, N. Brutsche, P. Herscovitch, W.C. Drevets, and C.A. Zarate Jr. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder Bipolar Disord. 16 2014 119 128
69. G.M. Chowdhury, K.L. Behar, W. Cho, M.A. Thomas, D.L. Rothman, and G. Sanacora (1)h-[(1)(3)c]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism Biol. Psychiatry 71 2012 1022 1025
70. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci.: Off. J. Soc. Neurosci. 17 1997 2921 2927
71. H. Homayoun, and B. Moghaddam NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons J. Neurosci.: Off. J. Soc. Neurosci. 27 2007 11496 11500
72. M.H. Chan, P.H. Chiu, C.Y. Lin, and H.H. Chen Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine Schizophr. Res. 136 2012 96 103
73. B.R. Cornwell, G. Salvadore, M. Furey, C.A. Marquardt, N.E. Brutsche, C. Grillon, and C.A. Zarate Jr. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression Biol. Psychiatry 72 2012 555 561
74. D.A. Luckenbaugh, M.J. Niciu, D.F. Ionescu, N.M. Nolan, E.M. Richards, N.E. Brutsche, S. Guevara, and C.A. Zarate Do the dissociative side effects of ketamine mediate its antidepressant effects? J. Affect. Disord. 159 2014 56 61
75. N. Dawson, B.J. Morris, and J.A. Pratt Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems Schizophr. Bull. 39 2013 366 377
76. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacol: Off. Publ. Am. Coll. Neuropsychopharmacol. 25 2001 455 467
77. N. DiazGranados, L.A. Ibrahim, N.E. Brutsche, R. Ameli, I.D. Henter, D.A. Luckenbaugh, R. Machado-Vieira, and C.A. Zarate Jr. Rapid resolution of suicidal ideation after a single infusion of an n-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder J. Clin. Psychiatry 71 2010 1605 1610
78. R.G. Thakurta, R. Das, A.K. Bhattacharya, D. Saha, S. Sen, O.P. Singh, and B. Bisui Rapid response with ketamine on suicidal cognition in resistant depression Indian J. Psychol. Med. 34 2012 170 175
79. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate Jr. A randomized add-on trial of an n-methyl-d-aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 2010 793 802
80. C.A. Zarate Jr., N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, A. Cravchik, J. Selter, C.A. Marquardt, V. Liberty, and D.A. Luckenbaugh Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Biol. Psychiatry 71 2012 939 946
81. J.W. Murrough, A.M. Perez, S. Pillemer, J. Stern, M.K. Parides, M. Aan Het Rot, K.A. Collins, S.J. Mathew, D.S. Charney, and D.V. Iosifescu Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol. Psychiatry 74 2013 250 256
82. D. Zigman, and P. Blier Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report J. Clin. Psychopharmacol. 33 2013 270 272
83. D. Thangathurai, and M. Mogos Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients J. Palliat. Med. 14 2011 389
84. R.B. Price, M.K. Nock, D.S. Charney, and S.J. Mathew Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression Biol. Psychiatry 66 2009 522 526
85. J.L. Hick, and J.D. Ho Ketamine chemical restraint to facilitate rescue of a combative "jumper" Prehospital Emerg. Care: Off. J. Natl. Assoc. EMS Physicians Natl. Assoc. State EMS Direct. 9 2005 85 89
86. J.R. Roberts, and G.K. Geeting Intramuscular ketamine for the rapid tranquilization of the uncontrollable, violent, and dangerous adult patient J. Trauma 51 2001 1008 1010
87. J.W. Murrough, A.M. Perez, S.J. Mathew, and D.S. Charney A case of sustained remission following an acute course of ketamine in treatment-resistant depression J. Clin. Psychiatry 72 2011 414 415
88. M. Liebrenz, A. Borgeat, R. Leisinger, and R. Stohler Intravenous ketamine therapy in a patient with a treatment-resistant major depression Swiss Med. Wkly. 137 2007 234 236
89. H.W. Goforth, and T. Holsinger Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy J. ECT 23 2007 23 25
90. M. Liebrenz, R. Stohler, and A. Borgeat Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry 10 2009 640 643
91. M. Messer, I.V. Haller, P. Larson, J. Pattison-Crisostomo, and C.E. Gessert The use of a series of ketamine infusions in two patients with treatment-resistant depression J. Neuropsychiatry Clin. Neurosci. 22 2010 442 444
92. J. Bjerre, and C. Fontenay Ketamine in melancholic depression Ugeskr. Laeger 172 2010 460 461
93. A.L. Womble Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder AANA J. 81 2013 118 119
94. A. De Gioannis, and D. De Leo Oral ketamine augmentation for chronic suicidality in treatment-resistant depression Austr. New Zeal. J. Psychiatry 48 2014 686
95. P. Clark Treatment-refractory depression: a case of successful treatment with intranasal ketamine 10% Ann. Clin. Psychiatry: Off. J. Am. Acad. Clin. Psychiatr. 26 2014 E10
96. D. D'Andrea, and R. Andrew Sewell Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion Biol. Psychiatry 74 2013 e13 e14
97. C. Harihar, P. Dasari, and J.S. Srinivas Intramuscular ketamine in acute depression: a report on two cases Indian J. Psychiatry 55 2013 186 188
98. R.B. Price, D.V. Iosifescu, J.W. Murrough, L.C. Chang, R.K. Al Jurdi, S.Z. Iqbal, L. Soleimani, D.S. Charney, A.L. Foulkes, and S.J. Mathew Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression Depress. Anxiety 31 2014 335 343
99. M. Aan Het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, D.S. Charney, and S.J. Mathew Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol. Psychiatry 67 2010 139 145
100. J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, C.E. Green, A.M. Perez, S. Iqbal, S. Pillemer, A. Foulkes, A. Shah, D.S. Charney, and S.J. Mathew Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am. J. Psychiatry 170 2013 1134 1142
101. K.A. Lapidus, C.F. Levitch, A.M. Perez, J.W. Brallier, M.K. Parides, L. Soleimani, A. Feder, D.V. Iosifescu, D.S. Charney, and J.W. Murrough A randomized controlled trial of intranasal ketamine in major depressive disorder Biol. Psychiatry 76 2014 970 976
102. J.W. Murrough, K.E. Burdick, C.F. Levitch, A.M. Perez, J.W. Brallier, L.C. Chang, A. Foulkes, D.S. Charney, S.J. Mathew, and D.V. Iosifescu Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 40 2015 1084 1090
103. P.R. Shiroma, C.S. Albott, B. Johns, P. Thuras, J. Wels, and K.O. Lim Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 17 2014 1805 1810
104. M.J. Niciu, B.D. Grunschel, P.R. Corlett, C. Pittenger, and M.H. Bloch Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder J. Psychopharmacol. 27 2013 651 654
105. S.A. Irwin, A. Iglewicz, R.A. Nelesen, J.Y. Lo, C.H. Carr, S.D. Romero, and L.S. Lloyd Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial J. Palliat. Med. 16 2013 958 965
106. K.A. Moore, E.M. Kilbane, R. Jones, G.W. Kunsman, B. Levine, and M. Smith Tissue distribution of ketamine in a mixed drug fatality J. Forensic Sci. 42 1997 1183 1190
107. B.R. Lalonde, and H.R. Wallage Postmortem blood ketamine distribution in two fatalities J. Anal. Toxicol. 28 2004 71 74
108. J.R. Gill, and M. Stajic Ketamine in non-hospital and hospital deaths in New York city J. Forensic Sci. 45 2000 655 658
109. R.J. Dinis-Oliveira, F. Carvalho, J.A. Duarte, R. Dias, T. Magalhaes, and A. Santos Suicide by hanging under the influence of ketamine and ethanol Forensic Sci. Int. 202 2010 e23 e27
110. M.J. Niciu, D.A. Luckenbaugh, D.F. Ionescu, S. Guevara, R. Machado-Vieira, E.M. Richards, N.E. Brutsche, N.M. Nolan, and C.A. Zarate Jr. Clinical predictors of ketamine response in treatment-resistant major depression J. Clin. Psychiatry 75 2014 e417 e423
111. T.J. Foster Suicide prevention as a prerequisite for recovery from severe mental illness Int. J. Psychiatry Med. 46 2013 15 25
112. J. Kasckow, K. Felmet, and S. Zisook Managing suicide risk in patients with schizophrenia CNS Drugs 25 2011 129 143
113. J.J. Griffiths, C.A. Zarate Jr., and J.J. Rasimas Existing and novel biological therapeutics in suicide prevention Am. J. Prev. Med. 47 2014 S195 S203
114. C.L. Ernst, and J.F. Goldberg Antisuicide properties of psychotropic drugs: a critical review Harv. Rev. Psychiatry 12 2004 14 41
115. K.E. Saunders, and K. Hawton The role of psychopharmacology in suicide prevention Epidemiol. Psichiatr. Soc. 18 2009 172 178
116. H.Y. Meltzer Suicide in schizophrenia: risk factors and clozapine treatment J. Clin. Psychiatry 59 Suppl. 3 1998 15 20
117. H.Y. Meltzer Treatment-resistant schizophrenia - the role of clozapine Curr. Med. Res. Opin. 14 1997 1 20
118. P.E. Keck Jr., S.M. Strakowski, and S.L. McElroy The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia J. Clin. Psychiatry 61 Suppl. 3 2000 4 9
119. H.Y. Meltzer Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options Curr. Psychiatry Rep. 4 2002 279 283
120. H.Y. Meltzer What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 4 2004 53 57
121. H.Y. Meltzer, and G. Okayli Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment Am. J. Psychiatry 152 1995 183 190
122. B. Spivak, S. Roitman, Y. Vered, R. Mester, E. Graff, Y. Talmon, N. Guy, N. Gonen, and A. Weizman Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine Clin. Neuropharmacol. 21 1998 245 250
123. A. Ciapparelli, L. Dell'Osso, S. Pini, M.C. Chiavacci, M. Fenzi, and G.B. Cassano Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study J. Clin. Psychiatry 61 2000 329 334
124. H.Y. Meltzer, L. Alphs, A.I. Green, A.C. Altamura, R. Anand, A. Bertoldi, M. Bourgeois, G. Chouinard, M.Z. Islam, J. Kane, R. Krishnan, J.P. Lindenmayer, and S. Potkin International Suicide Prevention Trial Study G. Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (intercept) Arch. Gen. Psychiatry 60 2003 82 91
125. A. Duggan, J. Warner, M. Knapp, and R. Kerwin Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK Br. J. Psychiatry 182 2003 505 508
126. W.H. Reid, M. Mason, and T. Hogan Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder Psychiatr. Serv. 49 1998 1029 1033
127. G. Ringback Weitoft, M. Berglund, E.A. Lindstrom, M. Nilsson, P. Salmi, and M. Rosen Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden - a register-based study Pharmacoepidemiol. Drug Saf. 23 2014 290 298
128. A.M. Mortimer, P. Singh, C.J. Shepherd, and J. Puthiryackal Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world Clin. Schizophr. Relat. Psychoses. 4 2010 49 55
129. B. Aukst-Margetic, B. Margetic, and V.B. Marsanic Suicidal obsessions as dose dependent side-effect of clozapine Psychopharmacol. Bull. 44 2011 65 69
130. A. Ishii, K. Mizoguchi, M. Kageoka, H. Seno, T. Kumazawa, and O. Suzuki Nonfatal suicidal intoxication by clozapine J. Toxicol. Clin. Toxicol. 35 1997 195 197
131. I. Modai, S. Hirschmann, A. Rava, R. Kurs, P. Barak, P. Lichtenberg, and M. Ritsner Sudden death in patients receiving clozapine treatment: a preliminary investigation J. Clin. Psychopharmacol. 20 2000 325 327
132. N. Tanriverdi, and K.M. Yazici Immediate recurrence of psychotic symptoms after discontinuation of clozapine: a case report Biol. Psychiatry 39 1996 814 815
133. S.J. Haas, M.N. Dennekamp, R. Wolfe, and T. Vos Beware the meta-analysis - clozapine and suicidal ideation Schizophr. Res. 86 2006 331 332
134. J. Hennen, and R.J. Baldessarini Suicidal risk during treatment with clozapine: a meta-analysis Schizophr. Res. 73 2005 139 145
135. G. Masi, S. Pisano, C. Pfanner, A. Milone, and A. Manfredi Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder J. Child Adolesc. Psychopharmacol. 23 2013 568 571
136. A. Nishiyama, and H. Matsumoto Quetiapine reduces irritability and risk of suicide in patients with agitated depression Tokai J. Exp. Clin. Med. 38 2013 93 96
137. J. Podobnik, I. Foller Podobnik, N. Grgic, D. Marcinko, and N. Pivac The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents Psychopharmacology (Berlin) 220 2012 639 641
138. A. Vita, L. De Peri, and E. Sacchetti Lithium in drinking water and suicide prevention: a review of the evidence Int. Clin. Psychopharmacol. 30 2015 1 5
139. T. Terao, S. Goto, M. Inagaki, and Y. Okamoto Even very low but sustained lithium intake can prevent suicide in the general population? Med. Hypotheses 73 2009 811 812
140. N. Ishii, T. Terao, Y. Araki, K. Kohno, Y. Mizokami, I. Shiotsuki, K. Hatano, M. Makino, K. Kodama, and N. Iwata Low risk of male suicide and lithium in drinking water J. Clin. Psychiatry 76 2015 319 326
141. N. Sugawara, N. Yasui-Furukori, N. Ishii, N. Iwata, and T. Terao Lithium in tap water and suicide mortality in Japan Int. J. Environ. Res. Public Health 10 2013 6044 6048
142. O. Giotakos, P. Nisianakis, G. Tsouvelas, and V.V. Giakalou Lithium in the public water supply and suicide mortality in Greece Biol. Trace Elem. Res. 156 2013 376 379
143. M. Helbich, V. Bluml, M. Leitner, and N.D. Kapusta Does altitude moderate the impact of lithium on suicide? A spatial analysis of Austria Geospat. Health 7 2013 209 218
144. N.D. Kapusta, N. Mossaheb, E. Etzersdorfer, G. Hlavin, K. Thau, M. Willeit, N. Praschak-Rieder, G. Sonneck, and K. Leithner-Dziubas Lithium in drinking water and suicide mortality Br. J. Psychiatry 198 2011 346 350
145. M. Helbich, M. Leitner, and N.D. Kapusta Geospatial examination of lithium in drinking water and suicide mortality Int. J. Health Geogr. 11 2012 19
146. V. Bluml, M.D. Regier, G. Hlavin, I.R. Rockett, F. Konig, B. Vyssoki, T. Bschor, and N.D. Kapusta Lithium in the public water supply and suicide mortality in Texas J. Psychiatr. Res. 47 2013 407 411
147. N. Kabacs, A. Memon, T. Obinwa, J. Stochl, and J. Perez Lithium in drinking water and suicide rates across the east of England Br. J. Psychiatry 198 2011 406 407
148. A. Cipriani, K. Hawton, S. Stockton, and J.R. Geddes Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ 346 2013 f3646
149. R.J. Baldessarini, L. Tondo, P. Davis, M. Pompili, F.K. Goodwin, and J. Hennen Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review Bipolar Disord. 8 2006 625 639
150. A. Cipriani, H. Pretty, K. Hawton, and J.R. Geddes Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials Am. J. Psychiatry 162 2005 1805 1819
151. F. Guzzetta, L. Tondo, F. Centorrino, and R.J. Baldessarini Lithium treatment reduces suicide risk in recurrent major depressive disorder J. Clin. Psychiatry 68 2007 380 383
152. B. Muller-Oerlinghausen Arguments for the specificity of the antisuicidal effect of lithium Eur. Arch. Psychiatry Clin. Neurosci. 251 Suppl. 2 2001 II72 II75
153. M. Bourgeois, J. Swendsen, F. Young, X. Amador, S. Pini, G.B. Cassano, J.P. Lindenmayer, C. Hsu, L. Alphs, H.Y. Meltzer, and P.T.S.G. InterSe Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial Am. J. Psychiatry 161 2004 1494 1496
154. M. Pompili, Z. Rihmer, X. Gonda, G. Serafini, L. Sher, and P. Girardi Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: the role of quetiapine XR in the treatment of unipolar and bipolar depression Riv. Psichiatr. 47 2012 489 497
155. Y. Dwivedi, H.S. Rizavi, R.C. Roberts, R.C. Conley, C.A. Tamminga, and G.N. Pandey Reduced activation and expression of erk1/2 map kinase in the post-mortem brain of depressed suicide subjects J. Neurochem. 77 2001 916 928
156. Y. Dwivedi, H.S. Rizavi, R.R. Conley, and G.N. Pandey Erk map kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream raf kinases raf-1 and b-raf Mol. Psychiatry 11 2006 86 98
157. S.C. Hsiung, M. Adlersberg, V. Arango, J.J. Mann, H. Tamir, and K.P. Liu Attenuated 5-ht1a receptor signaling in brains of suicide victims: Involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase J. Neurochem. 87 2003 182 194
158. F. Karege, N. Perroud, S. Burkhardt, M. Schwald, E. Ballmann, R. La Harpe, and A. Malafosse Alteration in kinase activity but not in protein levels of protein kinase b and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims Biol. Psychiatry 61 2007 240 245
159. Y. Dwivedi, H.S. Rizavi, R.R. Conley, R.C. Roberts, C.A. Tamminga, and G.N. Pandey Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase b in postmortem brain of suicide subjects Arch. Gen. Psychiatry 60 2003 804 815
160. M.A. Kohli, D. Salyakina, A. Pfennig, S. Lucae, S. Horstmann, A. Menke, S. Kloiber, J. Hennings, B.B. Bradley, K.J. Ressler, M. Uhr, B. Muller-Myhsok, F. Holsboer, and E.B. Binder Association of genetic variants in the neurotrophic receptor-encoding gene ntrk2 and a lifetime history of suicide attempts in depressed patients Arch. Gen. Psychiatry 67 2010 348 359
161. M. Kuloglu, B. Ustundag, M. Atmaca, H. Canatan, A.E. Tezcan, and N. Cinkilinc Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder Cell Biochem. Funct. 20 2002 171 175
162. A. Must, S. Koks, E. Vasar, G. Tasa, A. Lang, E. Maron, and M. Vali Common variations in 4p locus are related to male completed suicide Neuromol. Med. 11 2009 13 19
163. P.V. Choudary, M. Molnar, S.J. Evans, H. Tomita, J.Z. Li, M.P. Vawter, R.M. Myers, W.E. Bunney Jr., H. Akil, S.J. Watson, and E.G. Jones Altered cortical glutamatergic and gabaergic signal transmission with glial involvement in depression Proc. Natl. Acad. Sci. U. S. A. 102 2005 15653 15658
164. N.R. Smalheiser, G. Lugli, H.S. Rizavi, V.I. Torvik, G. Turecki, and Y. Dwivedi Microrna expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects PLoS ONE 7 2012 e33201
165. X.L. Jiang, B.X. Du, J. Chen, L. Liu, W.B. Shao, and J. Song Microrna-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through fgfr1 Int. J. Clin. Exp. Pathol. 7 2014 6760 6767
166. C.S. Jernigan, D.B. Goswami, M.C. Austin, A.H. Iyo, A. Chandran, C.A. Stockmeier, and B. Karolewicz The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder Progress Neuro-Psychopharmacol. Biol. Psychiatry 35 2011 1774 1779
167. K. Hashimoto, A. Sawa, and M. Iyo Increased levels of glutamate in brains from patients with mood disorders Biol. Psychiatry 62 2007 1310 1316
168. M. Beneyto, L.V. Kristiansen, A. Oni-Orisan, R.E. McCullumsmith, and J.H. Meador-Woodruff Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders Neuropsychopharmacol.: Off. Publ. Am. College of Neuropsychopharmacol. 32 2007 1888 1902
169. A. Deschwanden, B. Karolewicz, A.M. Feyissa, V. Treyer, S.M. Ametamey, A. Johayem, C. Burger, Y.P. Auberson, J. Sovago, C.A. Stockmeier, A. Buck, and G. Hasler Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)c]abp688 pet and postmortem study Am. J. Psychiatry 168 2011 727 734
170. A.M. Feyissa, A. Chandran, C.A. Stockmeier, and B. Karolewicz Reduced levels of nr2a and nr2b subunits of NMDA receptor and psd-95 in the prefrontal cortex in major depression Progress Neuro-psychopharmacol. Biol. Psychiatry 33 2009 70 75
171. M. Sowa-Kucma, B. Szewczyk, K. Sadlik, W. Piekoszewski, F. Trela, W. Opoka, E. Poleszak, A. Pilc, and G. Nowak Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims J. Affect. Disord. 151 2013 924 931
172. A.M. Feyissa, W.L. Woolverton, J.J. Miguel-Hidalgo, Z. Wang, P.B. Kyle, G. Hasler, C.A. Stockmeier, A.H. Iyo, and B. Karolewicz Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression Progress in Neuro-psychopharmacol. Biol. Psychiatry 34 2010 279 283
173. A.S. Gibbons, L. Brooks, E. Scarr, and B. Dean AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder J. Affect. Disord. 136 2012 1232 1237
174. A. Sequeira, F. Mamdani, C. Ernst, M.P. Vawter, W.E. Bunney, V. Lebel, S. Rehal, T. Klempan, A. Gratton, C. Benkelfat, G.A. Rouleau, N. Mechawar, and G. Turecki Global brain gene expression analysis links glutamatergic and gabaergic alterations to suicide and major depression PLoS ONE 4 2009 e6585
175. B. Karolewicz, K. Szebeni, C.A. Stockmeier, L. Konick, J.C. Overholser, G. Jurjus, B.L. Roth, and G.A. Ordway Low nnos protein in the locus coeruleus in major depression J. Neurochem. 91 2004 1057 1066
176. B. Karolewicz, C.A. Stockmeier, and G.A. Ordway Elevated levels of the nr2c subunit of the NMDA receptor in the locus coeruleus in depression Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 30 2005 1557 1567
177. A. Medina, S. Burke, R.C. Thompson, W. Bunney Jr., R.M. Myers, A. Schatzberg, H. Akil, and S.J. Watson Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder J. Psychiatr. Res. 47 2013 1150 1156
178. S. Erhardt, C.K. Lim, K.R. Linderholm, S. Janelidze, D. Lindqvist, M. Samuelsson, K. Lundberg, T.T. Postolache, L. Traskman-Bendz, G.J. Guillemin, and L. Brundin Connecting inflammation with glutamate agonism in suicidality Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 38 2013 743 752
179. M.A. Oquendo, G.P. Placidi, K.M. Malone, C. Campbell, J. Keilp, B. Brodsky, L.S. Kegeles, T.B. Cooper, R.V. Parsey, R.L. van Heertum, and J.J. Mann Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression Arch. Gen. Psychiatry 60 2003 14 22
180. G.M. Sullivan, M.A. Oquendo, M. Milak, J.M. Miller, A. Burke, R.T. Ogden, R.V. Parsey, and J.J. Mann Positron emission tomography quantification of serotonin(1a) receptor binding in suicide attempters with major depressive disorder JAMA Psychiatry 72 2015 169 178
181. Y.W. Yeh, P.S. Ho, C.Y. Chen, S.C. Kuo, C.S. Liang, K.H. Ma, C.Y. Shiue, W.S. Huang, C.Y. Cheng, T.Y. Wang, R.B. Lu, and S.Y. Huang Incongruent reduction of serotonin transporter associated with suicide attempts in patients with major depressive disorder: A positron emission tomography study with 4-[18f]-adam Int. J. Neuropsychopharmacol.: Off. Sci. J. Collegium Int. Neuropsychopharmacol. 18 2014 1 9
182. W.R. Marchand, J.N. Lee, C. Garn, J. Thatcher, P. Gale, S. Kreitschitz, S. Johnson, and N. Wood Striatal and cortical midline activation and connectivity associated with suicidal ideation and depression in bipolar ii disorder J. Affect. Disord. 133 2011 638 645
183. W.R. Marchand, J.N. Lee, S. Johnson, J. Thatcher, P. Gale, N. Wood, and E.K. Jeong Striatal and cortical midline circuits in major depression: Implications for suicide and symptom expression Progress in Neuro-psychopharmacol. Biol. Psychiatry 36 2012 290 299
184. W.R. Marchand, J.N. Lee, S. Johnson, P. Gale, and J. Thatcher Differences in functional connectivity in major depression versus bipolar ii depression J. Affect. Disord. 150 2013 527 532
185. E.D. Ballard, N. Lally, A.C. Nugent, M.L. Furey, D.A. Luckenbaugh, and C.A. Zarate Jr. Neural correlates of suicidal ideation and its reduction in depression Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 18 2015 10.1093/ijnp/pyu069
186. O. Malkesman, D.S. Pine, T. Tragon, D.R. Austin, I.D. Henter, G. Chen, and H.K. Manji Animal models of suicide-trait-related behaviors Trends Pharmacol. Sci. 30 2009 165 173
187. A. Preti Animal model and neurobiology of suicide Progress in Neuro-Psychopharmacol. Biol. Psychiatry 35 2011 818 830
188. A. Preti Do animals commit suicide? Does it matter? Crisis 32 2011 1 4
189. G. Fond, A. Loundou, C. Rabu, A. Macgregor, C. Lancon, M. Brittner, J.A. Micoulaud-Franchi, R. Richieri, P. Courtet, M. Abbar, M. Roger, M. Leboyer, and L. Boyer Ketamine administration in depressive disorders: a systematic review and meta-analysis Psychopharmacology (Berlin) 231 2014 3663 3676
190. C. Caddy, G. Giaroli, T.P. White, S.S. Shergill, and D.K. Tracy Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy Therap. Adv. Psychopharmacol. 4 2014 75 99
191. A. McGirr, M.T. Berlim, D.J. Bond, M.P. Fleck, L.N. Yatham, and R.W. Lam A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes Psychol. Med. 2014 1 12
192. K.G. Rasmussen, T.W. Lineberry, C.W. Galardy, S. Kung, M.I. Lapid, B.A. Palmer, M.J. Ritter, K.M. Schak, C.L. Sola, A.J. Hanson, and M.A. Frye Serial infusions of low-dose ketamine for major depression J. Psychopharmacol. (Oxford) 27 2013 444 450
193. E.D. Ballard, D.F. Ionescu, J.L. Vande Voort, M.J. Niciu, E.M. Richards, D.A. Luckenbaugh, N.E. Brutsche, R. Ameli, M.L. Furey, and C.A. Zarate Jr. Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety J. Psychiatr. Res. 58C 2014 161 166
194. P.R. Diamond, A.D. Farmery, S. Atkinson, J. Haldar, N. Williams, P.J. Cowen, J.R. Geddes, and R. McShane Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic J. Psychopharmacol. (Oxford) 28 2014 536 544
195. M.J. Niciu, D.A. Luckenbaugh, D.F. Ionescu, E.M. Richards, J.L. Vande Voort, E.D. Ballard, N.E. Brutsche, M.L. Furey, and C.A. Zarate Jr. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder Int. J. Neuropsychopharmacol./Off. Sci. J. Collegium Int. Neuropsychopharmacol. 18 2015 10.1093/ijnp/pyu039
196. J.X. Liu, E. Zerbo, and S. Ross Intensive ketamine use for multiple years: a case report Am. J. Addict./Am. Acad. Psychiatr. Alcohol. Addict. 24 2014 7 9